Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8CNS 4Gastrointestinal 3Gynecologic 2Dermatologic 2Breast 2Thoracic 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Sarcoma 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Urogenital Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma 1Histiocytoma, Malignant Fibrous 1Giant Cell Tumor of Bone 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Nivolumab 2tipifarnib 1olaparib 1lutetium Lu 177 dotatate 1fludarabine 1entinostat 1cixutumumab 1cabozantinib 1aldesleukin 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Molecular Diagnostic Techniques 1LY2940680 1Ipilimumab 1Immunotherapy 1Fentanyl 1Drug Therapy 1Cyclophosphamide 1CTLA-4 Antigen 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × fludarabine × Endocrine × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡